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 Abstract 
We aimed at comparing exhaled and non-exhaled non-invasive markers of respiratory inflammation in 
patients with COPD and healthy subjects and define their relationships with smoking habit. Forty-eight 
patients with stable COPD who were ex-smokers, 17 patients with stable COPD who were current 
smokers, 12 healthy current smokers and 12 healthy ex-smokers were included in a cross-sectional, 
observational study. Biochemical [prostaglandin (PG) E2, 15-F2t-isoprostane, fraction of exhaled nitric 
oxide (FENO)] and cellular (sputum cell counts) inflammatory outcomes and functional (spirometry) 
outcomes were measured in various biological matrices including exhaled breath condensate (EBC), 
exhaled breath, sputum supernatants, and urine. Sputum PGE2 was elevated in both groups of smokers 
compared with ex-smoker counterpart (COPD: P < 0.02; healthy subjects: P < 0.03), whereas EBC 
PGE2 was elevated in current (P = 0.0065) and ex-smokers with COPD (P = 0.0029) versus healthy ex-
smokers. EBC 15-F2t-isoprostane, a marker of oxidative stress, was increased in current and ex-
smokers with COPD (P < 0.0001 for both) compared with healthy ex-smokers, whereas urinary 15-F2t-
isoprostane was elevated in both smoker groups (COPD: P < 0.01; healthy subjects: P < 0.02) versus 
healthy ex-smokers. FENO was elevated in ex-smokers with COPD versus smoker groups (P = 0.0001 
for both). These data suggest that the biological meaning of these inflammatory markers depends on 
type of marker and biological matrix in which is measured. An approach combining different types of 
outcomes can be used for assessing respiratory inflammation in patients with COPD. Large studies are 
required to establish the clinical utility of this strategy. 
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 Introduction 
 
The pathophysiological role of prostaglandin (PG) E2, an endogenous eicosanoid which is generally 
considered pro-inflammatory [1,2], but can have anti-inflammatory effects in the respiratory system 
[3,4], and 15-F2t-isoprostane, a marker of lipid peroxidation [5], in chronic obstructive pulmonary 
disease (COPD) is largely not defined. PGE2 and 15-F2t-isoprostane are detected in the exhaled breath 
condensate (EBC) in healthy subjects [6,7] and their concentrations are elevated in this biological fluid 
in patients with stable COPD [8-10]. Compared with healthy chronic smokers and healthy nonsmokers, 
sputum PGE2 has been reported elevated in current smokers with COPD, but not in COPD patients who 
were ex-smokers [11]. Sputum 15-F2t-isoprostane concentrations were found elevated in patients with 
stable COPD as compared with healthy smokers, never-smokers and ex-smokers [12].  
However, the relationships between PGE2 and 15-F2t-isoprostane concentrations in EBC and sputum 
supernatants, which reflect inflammation at different levels of the respiratory system [13,14], is not 
defined. Elevated urinary 15-F2t-isoprostane concentrations in patients with COPD have been reported 
[15], but their relationships with 15-F2t-isoprostane concentrations in EBC and sputum are unknown. 
In the present study, the primary objective was to compare exhaled and non-exhaled non-invasive 
markers of respiratory inflammation in patients with COPD and healthy subjects and define their 
relationships with smoking habit. Secondary objectives were to clarify the relationships between PGE2 
concentrations in EBC and sputum supernatants, between 15-F2t-isoprostane concentrations in EBC, 
sputum supernatants and urine, and between lung and systemic inflammation by measuring 
independent markers of airway (fraction of exhaled nitric oxide (FENO), sputum inflammatory cells) 
and systemic inflammation/oxidative stress (urinary 15-F2t-isoprostane).  
 
 
 Methods 
 
Study subjects 
Forty-eight patients with stable COPD who were ex-smokers, 17 patients with stable COPD who were 
current smokers, 12 healthy current smokers and 12 healthy ex-smokers were studied. Diagnosis and 
classification of COPD was based on GOLD guidelines [16]. Diagnosis of COPD was based on history 
of smoking, symptoms of dyspnea, cough and sputum production, and the presence of post-
bronchodilator forced expiratory volume in one second (FEV1)/forced vital capacity (FVC) < 70% 
[16]. Patients had mild to severe COPD (GOLD stage 1-3) based on severity of airflow limitation [16]. 
Healthy subjects and patients with COPD who were ex-smokers and had been stopped smoking for at 
least 6 months. Healthy current smokers and patients with COPD who were current smokers were not 
allowed to smoke in the previous 12 h before study procedures. All patients with COPD had no history 
of asthma or other respiratory diseases, negative reversibility test to bronchodilators (inhalation of 
salbutamol at a dose of 400 µg), and negative skin prick tests results to common aeroallergens. Study 
subjects had stable COPD with no exacerbations or upper respiratory infections in the previous 4 
weeks. Details of pharmacological treatment are shown in Table 1. Patients with COPD were 
considered not on ICS if they were being steroid-naïve or had been stopping ICS for at least 8 weeks. 
All patients with COPD had never been on oral corticosteroids or had been stopping oral 
corticosteroids for at least 8 weeks.   
 
 
 
 
 
 Table 1. Subject characteristics. 
 
 Healthy ex-
smokers 
Healthy smokers COPD ex-smokers COPD current 
smokers 
     
N 12 12 48 17 
Gender, 
male/female  
9/3 10/2 36/12 12/5 
Age 56 ± 3.5 48 ± 3.3c 69 ± 1.3a 60 ± 2.5b,d 
FEV1, L 3.4 ± 0.2 3.7 ± 0.2 1.6 ± 0.1a 1.8 ± 0.1a 
FEV1, % pred 102.8 ± 3.0 100.9 ± 2.6 58.0 ± 2.4a,e 66.5 ± 3.5a 
FVC, L 4.1 ± 0.3 4.7 ± 0.2 2.6 ± 0.1a 2.8 ± 0.2a 
FVC, % pred 103.0 ± 3.4 106.0 ± 1.8  76.2 ± 2.3a 80.4 ± 3.8a 
FEV1/FVC 80.9 ± 1.4 77.9 ± 1.4 59.7 ± 1.5a,e 65.2 ± 1.8a 
Pack-years 18.0 (9.8-21.5) 22.5 (11.3-41.3) 40.0 (23.4-60.0)c 26.0 (20.0-57.5) 
GOLD stage 
(1/2/3) 
- - 35/12/1 15/2/0 
ICS, yes/no - - 12/36 7/10 
LABA, yes/no   15/33 7/10 
LAMA, yes/no   6/42 2/15 
§Data are expressed as mean ± SEM, except pack-years which are expressed as median and 25%-75% interquartile range. a, 
p<0.001, compared with healthy smokers and healthy ex-smokers; 
b, P<0.001compared with healthy smokers; c, P<0.01,compared with healthy ex-smokers; 
d, P<0.01, compared with COPD ex-smokers; e, P<0.05, compared with COPD current smokers 
Patients with COPD who were on ICS received fluticasone or the equivalent of fluticasone at a dose of 500 µg twice a day. 
Patients with COPD who were on LABA received the salmeterol or the equivalent of salmeterol at a dose of 50 µg twice a 
day. Patients with COPD who were on LAMA received tiotropium bromide at a dose of 18 µg once day via a DPI. 
Abbreviations: DPI, dry powder inhaler; FEV1, forced expiratory volume in one second; FVC, forced vital capacity; ICS, 
inhaled corticosteroids; LABA, long-acting beta2-receptor agonists; LAMA, long-acting muscarinic receptor antagonists. 
 
Study design 
This was a national, multicentre, observational, cross-sectional study. Participants were recruited in 
three centres: University of Modena and Reggio Emilia, COPD outpatient clinic, Modena, Italy; 
University of Parma, COPD outpatient clinic, Parma, Italy; Clinical Pharmacology and COPD 
outpatient clinic, University Hospital Agostino Gemelli, Catholic University of the Sacred Heart, 
Rome, Italy. Subjects attended on occasion for clinical examination, urinary collection, FENO 
measurement, EBC collection, pulmonary function tests, sputum induction and skin prick testing which 
were performed in this order.  
 Informed consent was obtained from patients. The study was approved by the Ethics Committee of the 
Catholic University of the Sacred Heart, Rome, Italy, of University of Modena and Reggio Emilia, 
Italy, and of University of Parma, Italy. 
 
Exhaled breath condensate sampling 
EBC was collected using a condenser (Ecoscreen, Jaeger, Hoechberg, Germany) as previously 
described [17] and according to standardised procedures [13]. Exhaled breath entered and left the 
chamber through one-way valves at the inlet and outlet, thus keeping the chamber closed. Subjects 
breathed tidally through a mouthpiece connected to the condenser for 15 minutes. EBC samples were 
stored at -80°C until analytical measurement. The condenser has a saliva trap to reduce the chance of 
salivary contamination. α-Amylase concentrations were measured in all EBC samples by an in vitro 
colorimetric method to check for possible salivary contamination (Roche Diagnostics, Basel, 
Switzerland).  
 
FENO measurement 
FENO was measured with the NIOX system (Aerocrine, Stockholm, Sweden) with a single breath on-
line method at constant flow of 50 ml/sec according to American Thoracic Society guidelines [19,20]. 
Exhalations were repeated after 1-minute relaxation period until the performance of three FENO values 
varies less than 10%. FENO measurements were obtained before spirometry. 
 
Measurement of PGE2 and 15-F2t-isoprostane in sputum supernatants and EBC  
15-F2t-isoprostane and PGE2 concentrations were measured by radioimmunoassays (RIAs) developed 
in our laboratory which were previously validated and compared with GC/MS and high performance 
liquid chromatography (HPLC) [21,22]. These RIAs have a sensitivity of 2 pg/ml. Intra-assay and 
 inter-assay coefficient of variation for 15-F2t-isoprostane were < 2% and < 3%, respectively; intra-
assay and inter-assay coefficient of variation for PGE2 were < 4% and < 5%, respectively [21]. 
 
Pulmonary function 
Spirometry was performed with a Pony FX spirometer (Cosmed, Rome, Italy) and the best of at least 
three acceptable FVC manoeuvres chosen [23]. Acceptable repeatability is achieved when both the two 
largest FVC and FEV1 values, respectively, are within 0.15 L of each other (0.1 L for subjects with a 
FVC ≤ 1.0 L) [23]. 
 
Sputum induction, processing and analysis 
Sputum induction, processing and analysis were performed according the ERS guidelines [24-25]. 
Baseline FEV1 was recorded before sputum induction. Subjects were pre-treated with inhaled 
salbutamol (400 µg), and, after 10 min, a spirometry was repeated [25]. Subjects were asked to inhale 
hypertonic saline (3%) for 5 min and, then, to rinse their mouths and try to expectorate into a sterilized 
box [25]. Five-minute inhalation sessions were repeated 4 times for a total of 20 minutes [25]. A 
spirometry was performed after each inhalation session to detect significant fall of FEV1. The 
procedure was stopped when approximately 1 g of plugs was collected, or if patients had symptoms 
or/and if FEV1 was reduced more than 20% over baseline values [25]. Sputum was processed within 2 
hours to ensure optimum cell counting and staining, with the sample always kept in ice [26].  
100-500 mg sputum free of salivary contamination was selected for sputum analysis. Dithiothreitol 
(DTT) 0.1% was added to sputum samples which were kept in a shaking rocker at room temperature 
for 20 minutes for sample homogenization [26]. Samples were filtered through a 48 µm nylon mesh 
into a pre-weighed conical tube and filtrate was weighed. Total cell count was performed manually 
 using a haemocytometer and cell viability was assessed by the trypan blue exclusion method before 
centrifugation [26]. 
To separate cell pellet from sputum supernatants, samples were centrifuged at 4°C for 10 minutes with 
a centrifugal force of 1200 x g [26]. Sputum supernatant samples were collected and stored at -80°C for 
measurement of PGE2 and 15-F2t-isoprostane concentrations. Cell pellets were resuspended in PBS 
buffer and cell concentrations were adjusted to 1 x 106 cells/ml. Cytospins were prepared by adding 40-
60 µl of cell resuspension to each cytospin and using a Shandon cytocentrifuge at 22 x g for 6 minutes 
[26]. Cytospins were stained for differential cell counts using Giemsa staining [26]. The differential 
cell counts was performed by counting a minimum of 400 nonsquamous cells and reported as the 
relative numbers of eosinophils, neutrophils, macrophages, lymphocytes, and bronchial epithelial cells, 
expressed as a percentage of total nonsquamous cells [26]. The percentage of squamous cells was 
reported separately. Slides with squamous cells > 30% of total cells were discarded. Slides were read 
blindly by two qualified and fully trained physicians. Monthly quality control was performed including 
internal slide reading and equipment calibration.  
 
Measurement of urinary 15-F2t-isoprostane 
Morning urinary samples (30-50 ml) were collected, additioned with 1 mM of the antioxidant 
compound 4-hydroxy TEMPO (Sigma Chem., Milan, Italy), snap frozen and kept at -80°C until 
analyzed. 2 ml of the sample were acidified with acetic acid and additioned with 20.000 dpm of 
internal standard (3H)-15-F2t-isoprostane. Following centrifugation, 15-F2t-isoprostane was purified by 
a double extraction procedure [22] with modifications as previously described [27], followed by 
quantification by an enzyme immunoassay (EIA) [22]. 
The first extraction was performed using bond-elut C18 cartridges activated with 1 ml methanol and 1 
ml water. After sample loading, the column was washed with 1 ml each of water, hexane and a 75:25 
 solution of hexane:ethylacetate. Samples were then eluted with 1 ml ethylacetate [22,27]. The second 
extraction was performed using bond-elut Si cartridges activated with 1 ml each of ethylacetate and 1:1 
hexane:ethylacetate [22,27]. Samples were additioned with 1 ml hexane, loaded and eluted with 1 ml 
methanol:ethylacetate, 20:80 [22,27]. The eluate was frozen at -20°C overnight and taken to dryness 
using a refrigerated centrifuge Savant, mod. SpeedVac. The dry residue was redissolved in 1.8 ml of 
EIA buffer and sonicated to allow optimal solubilisation [22,27]. An aliquot (0.2 ml) was used for 
recovery evaluation and different aliquots of the remaining sample were used for EIA using 
commercially available reagents (Cayman Chem. Co. Ann Arbor, MI, USA; SPI-BIO, Saclay, France). 
Results were corrected for the recovery of radiolabeled tracer and expressed as pg/mg creatinine. 
 
Skin testing 
Atopy was assessed by skin prick tests for common aeroallergens (Stallergenes, Antony, France). 
 
Statistical analysis 
Normally distributed values were expressed as mean ± SEM. Non-parametric values were expressed as 
medians and interquartile ranges (25th and 75th percentiles). Between-group comparison was performed 
by one-way ANOVA or Kruskal-Wallis test based on normal or non-parametric data distribution, 
respectively [28]. Correlation was expressed as Spearman’s correlation coefficient.  P value < 0.05 was 
considered statistically significant. Data were analyzed using Prism 5.0 (GraphPad Software, Inc., 
USA). 
 
 
 
 
 Results 
 
Subject characteristics are shown in Table 1. Both groups of patients with COPD were older than 
healthy control subjects (P < 0.001) (Table 1). Healthy smokers were younger than healthy ex-smokers 
(P < 0.01) (Table 1). 
α-Amylase concentrations were undetectable in all EBC samples, thus excluding significant salivary 
contamination. 
 
Pulmonary function 
Compared with healthy ex-smokers and healthy smokers, absolute pre-bronchodilator FEV1 values 
were reduced in patients with COPD who were ex-smokers (P < 0.001) and current smokers (P < 
0.001). Pre-bronchodilator FEV1% of the predicted value was lower in patients with COPD who were 
ex-smokers and current smokers compared with healthy ex-smokers (P < 0.001) and healthy smokers 
(P < 0.001). In our study, patients with COPD who were ex-smokers had lower FEV1% of the predicted 
value than patients with COPD who were current smokers (P < 0.05) (Table 1). Absolute FVC, FVC% 
of the predicted value, and FEV1/FVC ratio were reduced in both groups of COPD patients compared 
with healthy control subjects (P < 0.001), but were similar in COPD groups (Table 1).  
 
PGE2 concentrations in sputum supernatants 
PGE2 concentrations in sputum supernatants were measured in 37 patients with COPD who were ex-
smokers, 12 patients with COPD who were current smokers, 6 healthy smokers and 10 healthy ex-
smokers. The lower number of sputum samples analysed compared with the number of recruited 
patients reflects failure to induce sputum. PGE2 concentrations, expressed as median values and 
interquartile range, were measurable in all sputum supernatant samples.  
 PGE2 concentrations in sputum supernatants were as follows: 71.7 (46.2-125.6) pg/ml in healthy ex-
smokers, 227.5 (178.4-422.6) pg/ml in healthy smokers, 100.8 (62.9-240.4) pg/ml in patients with 
COPD who were ex-smokers and 218.2 (157.3-406.6) pg/ml in patients with COPD who were current 
smokers (Figure 1).  
 
Figure 1. PGE2 concentrations in sputum supernatants in healthy ex-smokers (HES) (n = 10), healthy smokers 
(HS) (n = 6), patients with COPD who were ex-smokers (COPD EX) (n = 37), and patients with COPD who 
were current smokers (COPD C) (n = 12). 
 
Compared with ex-smokers with COPD and healthy ex-smokers, PGE2 concentrations in sputum 
supernatants were elevated in current smokers with COPD (P < 0.02 and P < 0.004, respectively) and 
in healthy current smokers (P < 0.05 and P < 0.03, respectively) (Figure 1). Similar sputum PGE2 
concentrations were observed in patients with COPD who were current smokers and healthy current 
smokers (P = 0.96). 
 
15-F2t-isoprostane concentrations in exhaled breath condensate 
15-F2t-isoprostane concentrations in EBC were measured in 40 ex-smokers with COPD, 13 current 
smokers with COPD, 10 healthy smokers and 12 healthy ex-smokers. EBC 15-F2t-isoprostane 
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 concentrations were measurable in all samples, except two samples which were obtained from a 
healthy ex-smoker subject and from a current smoker with COPD.  
15-F2t-isoprostane concentrations, expressed as median values and interquartile range, were as follows:  
8 (6.0-8.8) pg/ml in healthy ex-smokers, 11.2 (6.4-18.8) pg/ml in healthy current smokers, 17.8 (8.8-
31.2) pg/ml in patients with COPD who were ex-smokers and 14.5 (7.9-18.6) pg in patients with 
COPD who were current smokers (Figure 2). Both group of patients with COPD had EBC 15-F2t-
isoprostane concentrations higher than those observed in healthy ex-smokers (ex-smokers with COPD: 
P < 0.001; current smokers with COPD: P < 0.01), but similar to those observed in healthy current 
smokers (P = 0.11) (Figure 2).  
 
Figure 2. 15-F2t-isoprostane concentrations in EBC in healthy ex-smokers (HES) (n = 11), healthy smokers (HS) 
(n = 10), patients with COPD who were ex-smokers (COPD EX) (n = 40), and patients with COPD who were 
current smokers (COPD C) (n = 12). 
 
There was a trend towards increased EBC 15-F2t-isoprostane concentrations in healthy current smokers 
compared with healthy ex-smokers which did not reach statistical significance (P = 0.098). Similar 
EBC 15-F2t-isoprostane concentrations were observed in both groups of patients with COPD (P = 0.30) 
(Figure 2). 
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 PGE2 concentrations in exhaled breath condensate 
PGE2 concentrations in EBC, expressed as median values and interquartile range, have been measured 
in 40 patients with COPD who were ex-smokers, 13 patients with COPD who were current smokers, 10 
healthy current smokers and 11 healthy ex-smokers. PGE2 concentrations were detected in all EBC 
samples.  
EBC PGE2 concentrations were as follows: 2.7 (1-7.7) pg/ml in healthy ex-smokers, 6.7 (4.9-17.6) 
pg/ml in healthy current smokers, 9.3 (6.0-30.3) pg/ml in patients with COPD who were ex-smokers 
and 10.9 (5.9-53.1) pg/ml in patients with COPD who were current smokers (Figure 3).  
 
Figure 3. PGE2 concentrations in EBC in healthy ex-smokers (HES) (n = 11), healthy smokers (HS) (n = 10), 
patients with COPD who were ex-smokers (COPD EX) (n = 40), and patients with COPD who were current 
smokers (COPD C) (n = 13). 
 
EBC PGE2 concentrations were elevated in both groups of patients with COPD (current smokers: P = 
0.0065; ex-smokers: 0.0029) compared with healthy ex-smokers, but not healthy current smokers 
(current smokers with COPD: P = 0.40; ex-smokers with COPD: P = 0.21). Similar EBC PGE2 
concentrations were observed in current smokers and ex-smokers with COPD (P = 0.53). PGE2 
increase in healthy current smokers compared with healthy ex-smokers did not reach statistical 
significance (P = 0.067).  
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15-F2t-isoprostane concentrations in sputum supernatants 
15-F2t-isoprostane concentrations were measured in sputum supernatants in 36 patients with COPD 
who were ex-smokers, 12 patients with COPD who were current smokers, 6 healthy current smokers 
and 9 healthy ex-smokers. 15-F2t-isoprostane was undetectable in 2 healthy ex-smokers and 6 patients 
with COPD who were ex-smokers. 15-F2t-isoprostane concentrations, expressed as median values and 
interquartile range, were as follows: 2.0 (1.3-3.2) pg/ml in healthy ex-smokers, 6.0 (5.7-18.3) pg/ml in 
healthy current smokers, 6.0 (2.8-20.3) pg/ml in patients with COPD who were ex-smokers and 11.0 
(6.0-14.6) pg/ml in patients with COPD who were current smokers. Patients with COPD who were 
current smokers had higher sputum 15-F2t-isoprostane concentrations than healthy ex-smokers (P = 
0.0007), but similar to those observed in healthy smokers (P = 0.34) and patients with COPD who were 
ex-smokers (P = 0.11). 
 
Urinary 15-F2t-isoprostane 
Urinary 15-F2t-isoprostane concentrations were measured in 42 patients with COPD who were ex-
smokers, 17 patients with COPD who were current smokers, 12 healthy current smokers and 12 healthy 
ex-smokers. 15-F2t-isoprostane was detected in all urinary samples. Urinary 15-F2t-isoprostane 
concentrations were as follows: 259.4 ± 33.7 pg/mg creatinine, mean ± SEM, in healthy ex-smokers, 
399.4 ± 44.3 pg/mg creatinine in healthy smokers, 343.6 ± 23.2 pg/mg creatinine in patients with 
COPD who were ex-smokers, and 483.4 ± 51.9 pg/mg creatinine in patients with COPD who were 
current smokers (Figure 4). Compared with healthy ex-smokers, urinary 15-F2t-isoprostane was 
elevated in healthy current smokers (P < 0.02) (Figure 4). Current smokers with COPD had higher 
urinary 15-F2t-isoprostane concentrations than ex-smokers with COPD (P < 0.01) and healthy ex-
smokers (P < 0.003), but similar to those observed in healthy current 
 difference in urinary 15-F2t-isoprostane concentrations between current smokers with COPD and 
healthy current smokers (P = 0.26) (Figure 4).  
 
Figure 4. Urinary 15-F2t-isoprostane concentrations in EBC in healthy ex-smokers (HES) (n = 12), healthy 
smokers (HS) (n = 12), patients with COPD who were ex-smokers (COPD EX) (n = 42), and patients with 
COPD who were current smokers (COPD C) (n = 17). 
 
FENO  
FENO was measured in 47 patients with COPD who were ex-smokers, 17 patients with COPD who 
were current smokers, 12 healthy current smokers and 12 healthy ex-smokers. FENO concentrations 
were detected in all study subjects (Figure 5). FENO concentrations were elevated in patients with 
COPD who were ex-smokers [16.1 (10.8-35.0) ppb, median and interquartile range] compared with 
patients with COPD who were current smokers [9.0 (5.9-11.0) ppb, P = 0.0001] and healthy smokers 
[7.4 (5.1-10.8) ppb, P = 0.0001] (Figure 5). Compared with healthy ex-smokers [10.4 (8.3-19.7) ppb], 
ex-smokers with COPD [16.1 (10.8-35.0) ppb] had higher FENO values, a difference which was very 
close to statistical significance (P = 0.0546).  
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Figure 5. Fraction of exhaled nitric oxide (FENO) concentrations in healthy ex-smokers (HES) (n = 12), healthy 
smokers (HS) (n = 12), patients with COPD who were ex-smokers (COPD EX) (n = 47), and patients with 
COPD who were current smokers (COPD C) (n = 17).  
 
Cellular analysis of induced sputum 
Cellular analysis of induced sputum was performed in 9 healthy ex-smokers, 6 healthy smokers, 29 
patients with COPD who were ex-smokers, and 11 patients with COPD who were current smokers. In 
the other study subjects, either it was not possible to induce sputum or samples were not suitable for 
analysis because of high salivary squamous cells (> 30% of total cells). Differential cell counts in 
induced sputum, expressed as percentage of total nonsquamous cells, are shown in Table 2. Neutrophil 
cell counts were elevated in patients with COPD who were ex-smokers compared with healthy ex-
smokers (P < 0.01) and patients with COPD who were current smokers (P < 0.04), but not healthy 
current smokers (P = 0.21) (Table 2). Likely due to relative increase in relative percentage of neutrophil 
cell counts, ex-smokers with COPD had lower macrophage cell counts than healthy ex-smokers (P < 
0.01), healthy smokers (P < 0.03) and current smokers with COPD (P < 0.02). No between-group 
differences were observed in relative percentage of eosinophil, lymphocyte, and bronchial epithelial 
cell counts. 
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 Table 2. Differential cell counts in induced sputum. 
 
 Healthy ex-
smokers 
Healthy smokers COPD ex-smokers COPD current 
smokers 
n 9 6 29 11 
Macrophages, % 85.0 (57.5-89.5) 85.5 (58.0-97.3) 47.0 (11.0-80.0)a,b,c 75.0 (65.0-92.0) 
Neutrophils, %  0 (0-1.5) 12.5 (0-25.0) 26.0 (1.0-82.5)a,d 3.0 (0-20.0) 
Eosinophils, % 1.0 (0-3.0) 0 (0-1.0) 0.5 (0-2.0) 0 (0-1.0) 
Lymphocytes, % 2.0 (0-8.0) 1.0 (1.0-2.0) 1.0 (0-7.0) 1.0 (1.0-12.0) 
Bronchial 
epithelial cells, % 
5.0 (2.5-9.5) 1.5 (1.0-3.0) 5.0 (0.25-10.0) 5.0 (1.0-6.0) 
§Data are expressed as median and 25%-75% interquartile range.  
a, P<0.01,compared with healthy ex-smokers; b, P<0.03 compared with healthy current smokers;  
c, P<0.02, compared with COPD current smokers; d, P<0.04, compared with COPD current smokers 
 
Correlations 
In patients with COPD who were ex-smokers, there was a correlation between 15-F2t-isoprostane and 
PGE2 concentrations in EBC (Spearman r = 0.55, P = 0.0002, n = 40) (Figure 6). No correlation was 
observed between other study outcomes. 
 
Figure 6. Correlation between 15-F2t-isoprostane and PGE2 concentrations in EBC in patients with COPD who 
were ex-smokers (Spearman r = 0.55, P = 0.0002, n = 40). 
 
Discussion 
In our study, we report 1) elevated PGE2 concentrations in sputum supernatants in both groups of 
current smokers; 2) elevated 15-F2t-isoprostane concentrations in EBC in both groups of patients with 
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 COPD; 3) elevated urinary 15-F2t-isoprostane concentrations in both groups of current smokers 
compared with the respective ex-smoker group; 4) elevated FENO in ex-smokers with COPD compared 
with both current smoker groups.  
Elevated sputum PGE2 concentrations in both current smoker groups as compared with their ex-smoker 
counterparts (COPD and healthy control subjects) and higher sputum PGE2 concentrations in healthy 
current smokers than in patients with COPD who were ex-smokers suggest that smoking itself can 
activate cyclo-oxygenase (COX) with subsequent increased airway PGE2 production independent of 
COPD. This data interpretation is further supported by in vitro data showing that cigarette smoke 
extract increases PGE2 release and COX-2 and PGE2 receptor expression in neutrophils and alveolar 
macrophages [11], suggesting that smoking promotes COX-2 induction.  
Unlike sputum PGE2, EBC PGE2 was elevated in both current and ex-smokers with COPD who had 
similar PGE2 concentrations. These data suggest that EBC PGE2 levels are more affected by COPD 
itself than smoking habit and are relatively independent of smoking cessation. This partially different 
pattern of EBC and sputum PGE2 concentrations might result from between-technique differences in 
their capacity of sampling the respiratory system as induced sputum is suitable for central airway 
sampling [13], whereas EBC has been successfully used for lower airway and alveolar sampling [14]. 
However, formal studies are required to define the origin of sputum and EBC markers in the respiratory 
system compartments. 
In line with previous studies, we observed elevated oxidative stress, as reflected by 15-F2t-isoprostane 
concentrations in EBC, in both groups of patients with COPD. Similar values in patients with COPD 
who were either current or ex-smokers might indicate that the increase in EBC 15-F2t-isoprostane is 
relatively independent of smoking cessation suggesting persistent oxidative stress consistent with 
previous reports [29,30]. In ex-smokers with COPD, the broad range of EBC 15-F2t-isoprostane values 
likely reflect a high inter-individual biological variability. In patients with COPD who were current 
 smokers, but not in ex-smokers with COPD, elevated 15-F2t-isoprostane concentrations in sputum 
supernatants confirm the increased oxidative stress observed by measuring 15-F2t-isoprostane in EBC. 
In view of the previously mentioned differential sampling capacity of EBC and sputum induction 
[13,14], the lack of complete concordance of sputum and EBC 15-F2t-isoprostane concentrations might 
suggest that, in current and ex-smokers with COPD, 15-F2t-isoprostane is produced, at least partially, at 
different levels of the respiratory system. In patients with COPD who were ex-smokers, we observed a 
correlation between EBC concentrations of PGE2 and 15-F2t-isoprostane, a marker of oxidative stress. 
The role of PGE2 in the respiratory system is not defined. As PGE2 can have both pro-inflammatory 
[1,2] and anti-inflammatory effects [3,4] in the respiratory system, the biological meaning of this 
correlation is unknown because it could reflect either increased respiratory inflammation which 
parallels elevated 15-F2t-isoprostane or a protective mechanism to counteract oxidative stress. 
We observed higher PGE2 concentrations in sputum supernatants than in EBC (median ratio ranging 
from 11 to 34 across study groups). In contrast, sputum and EBC 15-F2t-isoprostane concentrations 
were similar. This discrepancy might be explained by differences in biological matrix dilution, 
biomolecule distribution, technique sampling ability and compartment of biomolecule production 
within the respiratory system.  
We measured 15-F2t-isoprostane in EBC, sputum and urine. Urinary 15-F2t-isoprostane values were 
similar to those reported in previous studies [15,27]. The fact that the highest 15-F2t-isoprostane values 
were observed in urine likely reflects systemic production of this marker of oxidative stress and/or its 
increased stability in this biological matrix [5].  
The increase in FENO values in ex-smokers with COPD compared with healthy ex-smokers, which is 
very close to statistical significance (P = 0.0546), might suggest COPD-associated airway 
inflammation in this group of patients. Lower FENO concentrations in both groups of smokers possibly 
result from smoke-induced increase in production of reactive oxygen species which might convert NO 
 into peroxynitrite, thus, reducing FENO levels [31]. In addition to that, cigarette smoke reduces 
inducible nitric oxide synthase (NOS) activity in lung epithelial cells [32] and endothelial NOS in 
pulmonary artery endothelial cells [33].  
Relative percentage of sputum neutrophil cell counts was increased in ex-smokers with COPD 
compared with healthy ex-smokers in line with COPD-induced airway inflammation. Higher sputum 
neutrophils in ex-smokers with COPD than in current smokers with COPD is difficult to explain and 
might be related to between-group differences in smoking history and/or airway/lung bacteriological 
profiles. However, sputum bacteriological analysis was not performed. 
Our study has strengths. All the techniques used for assessing inflammation/oxidative stress are non-
invasive, except sputum induction, which is semi-invasive; the methodology used is reliable as PGE2 
and 15-F2t-isoprostane were measured with techniques previously validated by GC/MS or HPLC 
[7,21,22], which are analytical gold standard, whereas EBC sampling [18], FENO measurement [19,15], 
and sputum induction and analysis [24-26] were performed according to international guidelines; in 
study groups, the same panel of outcomes, including systemic (urinary 15-F2t-isoprostane) and 
respiratory (sputum and EBC PGE2 and 15-F2t-isoprostane, FENO, sputum cell counts) markers, was 
measured making it possible to compare inflammation/oxidative stress at the systemic and local level in 
the same cohort; measurement of PGE2 in EBC and sputum and 15-F2t-isoprostane in EBC, sputum and 
urine, enables concentration comparison of the same outcome measures in various biological matrices; 
the effect of smoking habit and COPD itself can be studied due to the inclusion of healthy control 
groups (current smokers and ex-smokers).  
However, our study has some limitations. A possible effect of age on inflammatory outcome measures 
cannot be excluded as healthy current smokers were younger than other study groups. Ex-smokers with 
COPD had a heavier smoking history than healthy current smokers based on pack-years and more 
severe airway limitation than current smokers with COPD based on FEV1 and FEV1/FVC values. 
 PGE2 concentrations were detected in all EBC samples, although in some cases, particularly in healthy 
ex-smokers, were close to the analytical sensitivity where the variability is higher. Likewise, sputum 
15-F2t-isoprostane data should be interpreted cautiously as concentrations were undetectable in 6 ex-
smokers with COPD and 2 healthy ex-smokers and, in some cases, were close to the analytical 
detection limit. This is a relatively small study which requires larger confirmatory studies. 
 
Conclusion 
The biological meaning of the inflammatory markers measured in this study depends on type of marker 
and biological matrix in which is measured. We propose a holistic, integrated, approach to the patient 
with COPD based on measurement of exhaled and non-exhaled non-invasive markers of respiratory 
and systemic inflammation/oxidative stress that combines functional, cellular and molecular outcomes. 
This strategy has potential and therapeutic implications and might translate into a more complete 
characterization of individual patients with COPD. However, larger studies and external validation are 
required to clarify the clinical utility of this approach. 
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